Table 1. Characteristics of randomized study participants
Figure 1. Subject disposition.
Table 2. Antigen and adjuvant composition of vaccines administered
Table 3. Immunogenicity analyses: HPV 6, 11, 16, and 18
Figure 2. Anti-HPV31, 45, 52, and 58 GMTs in Study 1 at one month post-dose 3; B) Interim analysis of anti-HPV31, 33, 45, 52, and 58 GMTs in Study 2 at one month post-dose 2.
Table 4. Adverse event (AE) summary
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
